Development and validation of a predictive model to guide the use of plerixafor in pediatric population - Takeaways - MDSpire

Development and validation of a predictive model to guide the use of plerixafor in pediatric population

  • By

  • Bernard Sebastien

  • Peter Cheverton

  • Catherine Magnin

  • Jihane Aouni

  • Remi Castan

  • September 26, 2022

  • 0 min

Share

  • 1

    Plerixafor enhances mobilization of hematopoietic stem cells (HSCs) in pediatric patients undergoing autologous transplantation.

  • 2

    The MOZAIC trial demonstrated that plerixafor combined with G-CSF significantly improves successful mobilization rates in children.

  • 3

    A predictive model was developed to correlate peripheral blood CD34+ counts with collected CD34+ cells during apheresis.

  • 4

    The linear model showed a high correlation (r = 0.84) between pre-apheresis PB-CD34+ counts and post-apheresis CD34+ yields.

  • 5

    Mobilization algorithms can optimize plerixafor use in pediatric patients at higher risk for mobilization failure.

Original Source(s)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population

  • by Bernard Sebastien, Peter Cheverton, Catherine Magnin, Jihane Aouni, Remi Castan

  • September 26, 2022

Related Content

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min
Refining CAR-NK Design

Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

  • March 4, 2026

  • 2 min
Prognostic Implications of Widespread FDG Uptake in Spleen and/or Bone Marrow Linked to Reticuloendothelial System Activation in Patients with Lymphoma